Molecular Determinants of the Cardiometabolic Phenotype

Author(s): Lisa de las Fuentes, Giovanni de Simone, Donna K. Arnett, Victor G. Davila-Roman

Journal Name: Endocrine, Metabolic & Immune Disorders - Drug Targets
Formerly Current Drug Targets - Immune, Endocrine & Metabolic Disorders

Volume 10 , Issue 2 , 2010

Become EABM
Become Reviewer
Call for Editor


The metabolic syndrome represents a clustering of risk factors that has been shown to predict adverse cardiovascular outcomes. Although the precise mechanisms contributing to the cardiometabolic syndrome (CMS) remain poorly defined, accumulating evidence identifies two intersecting candidate pathways responsible for inflammation and energy homeostasis in the pathophysiology that underlie cardiometabolic traits. Although currently no pharmacologic interventions specifically target CMS, future drug development efforts should attempt to capitalize on molecular nodes at the intersections of these pathways in the CMS.

Keywords: Metabolic syndrome, cardiometabolic syndrome, substrate metabolism, inflammation, obesity, insulin resistance, hypertension, dyslipidemia

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2010
Page: [109 - 123]
Pages: 15
DOI: 10.2174/187153010791213119
Price: $65

Article Metrics

PDF: 7